Dec 15, 2025 · GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, …

Multi-cancer early detection (MCED) testing is a new approach to screening for cancer. Adding a blood-based multi-cancer early detection test can help screen for many of the deadliest cancers that don’t …

The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration.

We have a group of people at GRAIL whose talent, commitment, and creativity are unmatched. And as we grow, we’re looking for people who will increase the impact we can make on the world.

The test detected cell-free DNA from cancer present in the mother’s blood. In 2016, Illumina spun out a separate entity to focus on researching this incredible discovery, naming it GRAIL because the co …

To pursue a mission like GRAIL’s, it takes all of us—a unified collective of courageous, adaptable, and open-minded big thinkers dedicated to creating a better world.

GRAIL Presents Positive Analytical Validation Data on its Methylation-Based Post-Diagnostic Cancer Research Solution at American Association for Cancer Research (AACR) Annual Meeting 2023

Nov 18, 2025 · GRAIL, Inc. Investor relations (IR) website contains information about our business for stockholders, potential investors, and financial analysts.

We are committed to the utmost scientific rigor and have enrolled over 300,000 participants in a clinical study program to demonstrate broad applicability of our multi-cancer early detection technologies. To …

Jun 18, 2025 · GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, …